This contract expires in 83 days (Sep 29, 2026).
THE CORPORATION OF MERCER UNIVERSITY - IN VITRO TESTS TO SUPPORT BIOEQUIVALENCE DETERMINATION WHEN GENERIC DERMATOLOGICAL FORMULATION HAS DIFFERENCES FROM THE BRAND PRODUCT FORMULATION
Key Details
Description
IN VITRO TESTS TO SUPPORT BIOEQUIVALENCE DETERMINATION WHEN GENERIC DERMATOLOGICAL FORMULATION HAS DIFFERENCES FROM THE BRAND PRODUCT FORMULATION
Context & Analysis
On Dec 9, 2025, Department of Health and Human Services obligated $375,476 to THE CORPORATION OF MERCER UNIVERSITY for in vitro tests to support bioequivalence determination when generic dermatological formulation has differences from the brand product formulation. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in MACON, GA. The contract is scheduled through Sep 29, 2026 — approximately 3 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.